2. Signaling Pathways
  3. Immunology/Inflammation
  4. Mucin
  5. Mucin Inhibitor

Mucin Inhibitor

Mucin Isoform Comparison

Mucin Inhibitors (22):

Cat. No. Product Name Effect Purity
  • HY-177442
    DS-3939a
    		Inhibitor 99.15%
    DS-3939a (DS-3939) is an anti-TA-MUC1 (tumor-associated mucin-1) antibody-drug conjugate (ADC). DS-3939a consists of a humanized anti-TA-MUC1 IgG1 monoclonal antibody Gatipotuzumab ( HY-P99634), a stable and cleavable tetrapeptide-based linker (Gly-Gly-Phe-Gly), and a DNA topoisomerase I inhibitor payload (DXd) (HY-13631D), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). DS-3939a inhibits the growth of TA-MUC1-positive cancer cells (CFPAC-1, NCI-H2110) by inducing DNA damage and apoptosis. DS-3939a exhibits significant antitumor activity in a variety of TA-MUC1-expressing advanced solid tumors. DS-3939a can be used for the study of TA-MUC1-expressing advanced cancers.
  • HY-P99237
    Sofituzumab
    		Inhibitor
    Sofituzumab (MMUC 1206A) is an anti-MUC16 antibody with a Kd of 0.3-0.9 nM. Sofituzumab can bind multiple adjacent antibody molecules to the repeat sequences of the same MUC16 molecule. Sofituzumab exhibits no anti-tumor activity in the HPAC pancreatic adenocarcinoma xenograft model.
  • HY-P992091
    Nacolomab
    		Inhibitor
    Nacolomab is an anti-human monoclonal antibody targeting MUC1/CD227. Nacolomab can be used for the research of cancer.
  • HY-P992131
    Sacomitatug
    		Inhibitor
    Sacomitatug is a humanized IgG1-κ monoclonal antibody targeting mucin 1 (MUC1). Sacomitatug exerts anti-tumor effects by blocking MUC1-mediated tumor proliferation signals and activating immune effectors.
  • HY-P99732
    Minretumomab
    		Inhibitor
    Minretumomab (CC-49) is a murine monoclonal antibody against TAG-72 (tumor-associated glycoprotein 72). Minretumomab is used in cancer and immunity research.
  • HY-P99591
    Sontuzumab
    		Inhibitor 99.66%
    Sontuzumab (AS1402) is a humanizedised IgG1κ MUC1 specific monoclonal antibody. Sontuzumab binds the extracellular MUC1 peptide sequence PDTR with a Kd of ~1 nM. Sontuzumab can be used for the research of breast cancer.
  • HY-N1510
    Kaempferol 3-O-gentiobioside
    		Inhibitor 99.88%
    Kaempferol 3-O-gentiobioside is an orally active flavonoid, with a Ka value of 57 µM against human NOTCH1 and an IC50 value of 50 μM against α-glucosidase. Kaempferol 3-O-gentiobioside inhibits the NOTCH signaling pathway. It downregulates the expression of TLR4 and NLRP3, and suppresses the activation and nuclear translocation of NF-κB. Kaempferol 3-O-gentiobioside inhibits the expression of MUC5AC, reduces nitrite and ROS levels, and attenuates excessive mucus secretion. It exhibits antibacterial activity, reducing the formation and growth of MRSA biofilms. Kaempferol 3-O-gentiobioside blocks the TGF-β/ALK5/Smad signaling pathway and inhibits epithelial-mesenchymal transition. It suppresses the proliferation, migration, invasion and metastatic growth of tumor cells. Kaempferol 3-O-gentiobioside alleviates airway inflammation and mucus hypersecretion in mice with allergic asthma. It reduces the volume of ovarian cancer xenografts in mice. Kaempferol 3-O-gentiobioside can be used in research related to allergic asthma, diabetes, MRSA infection, breast cancer, gastric cancer and ovarian cancer.
  • HY-168973
    Fexlamose
    		Inhibitor 99.93%
    Fexlamose (AER-01) is a thiol-modified carbohydrate agent with mucolytic property. Fexlamose cleaves disulfides to cause mucolysis. Fexlamose can be used for researchs of chronic obstructive pulmonary disease (COPD) and muco-obstructive lung diseases (MOLD).
  • HY-P99968
    Clivatuzumab
    		Inhibitor ≥99.0%
    Clivatuzumab is a humanized anti-mucin monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancers.
  • HY-P99362
    Ensituximab
    		Inhibitor 99.93%
    Ensituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC. Ensituximab shows specificity to colorectal and pancreatic cancer.
  • HY-P990831
    Anti-MUC1/CD227 Antibody (C595 (NCRC48))
    		Inhibitor
    Anti-MUC1/CD227 Antibody (C595 (NCRC48)) is a kind of mouse IgG3 κ chimeric antibody inhibitor, targeting to human MUC1/CD227. Anti-MUC1/CD227 Antibody (C595 (NCRC48)) specifically recognizes and binds to the MUC1 protein, which is overexpressed and abnormally glycosylated on the surface of tumor cells, thereby precisely killing cancer cells. Anti-MUC1/CD227 Antibody (C595 (NCRC48)) can be used for the researches of cancer, such as ovarian cancer.
  • HY-160109A
    Ac5GalNTGc epimer
    		Inhibitor 98.39%
    Ac5GalNTGc epimer is an analogue of hexosamine and the racemate of Ac5GalNTGc (HY-160109). Ac5GalNTGc is a potent, peracetylated C-2 thioglycolyl-substituted GalNAc analog that efficiently inhibits mucin-type O-glycan biosynthesis. Ac5GalNTGc reduces leukocyte sialyl-Lewis-X expression and inhibits L-/P-selectin mediated rolling under flow, as well as P-selectin dependent leukocyte-platelet adhesion. Ac5GalNTGc exhibits anti-inflammatory activity in a thioglycollate-induced acute peritonitis model. Ac5GalNTGc can be used for studies of O-glycan/mucin biology, inflammation, and related translational research.
  • HY-P1925B
    L-GO-203 TFA
    		Inhibitor 98.69%
    L-GO-203 TFA is a potent MUC1-C oncoprotein inhibitor. L-GO-203 TFA is an anti-cancer peptide for targeting intracellular proteins.
  • HY-P991608
    CTM01
    		Inhibitor
    CTM01 is a murine IgG1 (or humanized IgG4) monoclonal antibody inhibitor targeting MUC1. CTM01 has a broad spectrum anticancer activity against solid tumors of epithelial origin, such as breast, lung and ovarian cancer.
  • HY-P991166
    Ubletamig
    		Inhibitor
    Ubletamig is an anti-MUC16 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 kappa, Isotype Control (HY-P99003).
  • HY-158333
    Tasuldine
    		Inhibitor
    Tasuldine is a mucolytic agent, which decreases the sialomucin content of mucus, improves mucociliary and cough clearance.
  • HY-P991317
    BTH1704
    		Inhibitor
    BTH1704 is a human monoclonal antibody (mAb) targeting MUC1. BTH1704 enables PGG-primed leukocytes to kill iC3b-opsonized tumor cells. BTH1704 can be used in pancreatic and breast cancer research.
  • HY-P992374
    huDMB5F3
    		Inhibitor
    huDMB5F3 (DMB5F3; chDMB5F3) is a human monoclonal antibody against human CD227/MUC1, with a Ka value of 5.89 pM for its human target. huDMB5F3 enters MUC1-positive cancer cells via a temperature-dependent internalization process. huDMB5F3 induces cytotoxicity in MUC1-positive cancer cells. huDMB5F3 can be used in the research of various cancers including breast cancer, pancreatic cancer and gastric cancer.
  • HY-P992096
    Pemtumomab Antibody
    		Inhibitor
    Pemtumomab Antibody (R-1549) is an anti-MUC1 monoclonal antibody. Pemtumomab Antibody can be used in research related to breast cancer and other cancers.
  • HY-P991318
    AR20.5
    		Inhibitor
    AR20.5 is a human monoclonal antibody (mAb) targeting MUC1. AR20.5 increases the number of activated CD8 T cells, CD3+CD4−CD8−(DN) T cells, and mature dendritic cells in pancreatic tumor-bearing mice. AR20.5 can be used in anti-pancreatic cancer immunity research.